Faron Pharmaceuticals Oy Faron's Financial Calendar for 2024 (6853X)
22 December 2023 - 6:00PM
UK Regulatory
TIDMFARN
RNS Number : 6853X
Faron Pharmaceuticals Oy
22 December 2023
Faron Pharmaceuticals Oy
("Faron" or "Company")
Faron's Financial Calendar for 202 4
Company announcement
TURKU, FINLAND / BOSTON, MA - December 22, 2023 - Faron
Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical
stage biopharmaceutical company focused on tackling
difficult-to-treat cancers and inflammation via precision
immunotherapy, today announces the following dates for the
Company's financial reporting in 202 4 :
February Financial statement release for the full year 202 3 and
2 9 Annual Report 202 3 including financial statements for
the full year
August 2 Half-year financial report for the period January 1 to
7 June 30, 202 4
The annual general meeting is planned to be held on March 2 2 ,
202 4 . A separate stock exchange notice will be issued by Faron's
Board of Directors to convene the meeting.
For more information please contact:
Investor Contact
LifeSci Advisors
Daniel Ferry
Managing Director
daniel@lifesciadvisors.com
+1 (617) 430-7576
ICR Consilium
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: Faron@consilium-comms.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global,
clinical-stage biopharmaceutical company, focused on tackling
cancers via novel immunotherapies. Its mission is to bring the
promise of immunotherapy to a broader population by uncovering
novel ways to control and harness the power of the immune system.
The Company's lead asset is bexmarilimab, a novel anti-Clever-1
humanized antibody, with the potential to remove immunosuppression
of cancers through targeting myeloid cell function. Bexmarilimab is
being investigated in Phase I/II clinical trials as a potential
therapy for patients with hematological cancers in combination with
other standard treatments treatments and as a monotherapy in last
line solid cancers . Further information is available at
www.faron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDUAABRONUUUAA
(END) Dow Jones Newswires
December 22, 2023 02:00 ET (07:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024